Özgen Özge, Çetin İdil, Atalar Fatmahan, Topçul Mehmet Rıfkı
Aziz Sancar Institute of Experimental Medicine, Molecular Medicine Department, Istanbul University, Istanbul Turkiye.
Advanced Cancer and Pharmaceutical Biotechnologies Research Unit, Faculty of Science, Department of Biology, Istanbul University, Istanbul, Turkiye.
Cell Mol Biol (Noisy-le-grand). 2025 Feb 2;71(1):52-59. doi: 10.14715/cmb/2025.70.1.6.
In the pursuit of more effective breast cancer therapies, the investigation of interactions between novel compounds and established chemotherapeutics has become increasingly important. This study investigates the combinatory effects of alpha-mangostin (α-MG) and nab-paclitaxel on MCF-7 and MDA-MB-231 cell lines, utilizing the xCELLigence RTCA system for continuous real-time cellular analysis, BrdU incorporation assays for proliferation assessment, and the quantification of mitotic activity and caspase-3/7 levels to elucidate apoptotic mechanisms. Our findings demonstrate that both α-MG and nab-paclitaxel independently induce significant inhibition of cellular proliferation and modulate cell cycle dynamics over a 24 to 72-hour period. Notably, when combined, these agents exhibit a pronounced enhancement of cell cycle inhibition and apoptosis, surpassing the effects observed with monotherapy. This potentiation effect suggests that α-MG augments the therapeutic efficacy of nab-paclitaxel, potentially allowing for reduced dosages in clinical applications. The study underscores the potential of α-MG as an adjuvant in breast cancer treatment, offering a promising strategy to optimize therapeutic regimens, minimize adverse effects, and improve patient outcomes in clinical oncology.
在追求更有效的乳腺癌治疗方法的过程中，研究新型化合物与已有的化疗药物之间的相互作用变得越来越重要。本研究利用xCELLigence RTCA系统进行连续实时细胞分析、采用BrdU掺入试验评估增殖情况，并通过定量有丝分裂活性和caspase-3/7水平来阐明凋亡机制，研究了α-山竹黄酮（α-MG）和纳米白蛋白结合型紫杉醇对MCF-7和MDA-MB-231细胞系的联合作用。我们的研究结果表明，α-MG和纳米白蛋白结合型紫杉醇在24至72小时内均可独立显著抑制细胞增殖并调节细胞周期动力学。值得注意的是，联合使用时，这些药物对细胞周期的抑制和凋亡作用显著增强，超过了单药治疗的效果。这种增效作用表明α-MG可增强纳米白蛋白结合型紫杉醇的治疗效果，可能允许在临床应用中降低剂量。该研究强调了α-MG作为乳腺癌治疗辅助药物的潜力，为优化治疗方案、最小化不良反应以及改善临床肿瘤学患者的预后提供了一种有前景的策略。
